# Progress Note 06 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Frédéric Chopin (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI020-SYN
- Date: 2026-07-21
- Fictional facility: St. Posthumous Health Center
- Fictional author: Matthias Lindqvist, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

End-of-treatment review after 119 doses. **S**

## History of present illness

Mr. Chopin returns five days after his 119th and last dose. He took every dose on his video calls, 56 in the intensive phase and 63 in the continuation phase, finishing in 17 weeks. The two-month culture grew nothing, so he has two consecutive negative cultures. The cold he had in June cleared within ten days. He has no cough, sputum, fever, night sweats, or blood, and he weighs 55.0 kg, 6.5 kg more than at diagnosis. He had no tendon pain or tingling at any point. Between the sick visit and today there was no clinic review; the health department nurse asked about symptoms and side effects on every video call. He is teaching his full schedule of fifteen students and has started practicing for a small recital. **S**

| Element | Detail |
|---|---|
| Treatment | 119 of 119 doses observed, completed in 17 weeks |
| Cultures | Third-week and two-month cultures negative |
| Weight | 55.0 kg, up 6.5 kg since diagnosis |
| Work | Teaching fifteen students a week |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Respiratory | Negative | No cough, sputum, hemoptysis, or breathlessness |
| Constitutional | Negative | No fever, night sweats, or weight loss |
| Musculoskeletal | Negative | No tendon pain |
| Neurological | Negative | No numbness or tingling |
| Psychiatric | Negative | Mood good; PHQ-9 3; no thoughts of suicide or self-harm |

5 systems reviewed. **S**

## Current medications

- No current medications. **S**

## Allergies

- No known allergy **S**

## Objective

BP 110/70 mmHg; pulse 72 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 55 kg; BMI 19 kg/m². All vital signs are synthetic.

Hemoglobin: 14.1 g/dL; Albumin: 4 g/dL; ALT: 22 U/L; PHQ-9: 3. All results are synthetic.

## Change since baseline

- Hemoglobin: 12.1 g/dL (low) at baseline, 14.1 g/dL at this visit **S**
- Albumin: 3.2 g/dL (low) at baseline, 4 g/dL at this visit **S**
- ALT: 18 U/L at baseline, 22 U/L at this visit **S**
- PHQ-9: 7 at baseline, 3 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 55.0 kg, BMI 19.0 |
| Respiratory | Clear, with no crackles |
| Abdomen | Liver not enlarged |
| Musculoskeletal | Tendons non-tender |
| Neurological | Normal sensation and fine finger movements |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Drug-susceptible pulmonary tuberculosis, treatment completed** (A15.0). Treatment completed under the 119-dose rule within five months, with culture conversion and a full clinical response. The chest X-ray today shows the cavity closed with a small area of right upper lobe scarring. Hemoglobin 14.1, albumin 4.0, and ALT 22 are normal. Dr. Kowalczyk-Grant reviewed the results by message and advises no routine follow-up. **S**
   - No further tuberculosis medicine.
   - Return the same day for a cough lasting more than two to three weeks, fever, night sweats, hemoptysis, or weight loss.
   - Today's X-ray is the baseline for any future comparison.
   - Health department notified that treatment is complete.
2. **Moderate protein-calorie malnutrition, resolved** (E44.0). Weight 55.0 kg (BMI 19.0) and albumin 4.0: goal met. **S**
   - Stop the supplement drinks; keep three meals and two snacks a day.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Symptom review: cough, sputum, hemoptysis, fever, night sweats | Every visit | Completed today | No symptoms |
| Examination | Weight, with the pyrazinamide dose checked against the weight band | Monthly | Completed today | 55.0 kg |
| Medication safety | Adverse effects: hepatitis symptoms, tendon pain, numbness or tingling, rash, nausea, orange body fluids | Every visit | Completed today | None at any visit or video call |
| Examination | Clinical review (adherence, symptoms, adverse effects, weight) | At least monthly during treatment | Deferred | No clinic review between the sick visit in early June and today, about six weeks, because the schedule went from the end of the intensive phase to the end of treatment. The nurse reviewed symptoms and side effects on every video call, and today's examination, weight, and tests are normal, so no harm is evident. Corrective action: monthly clinic reviews booked at the start of treatment for every patient on the four-month regimen |
| Laboratory | Liver tests (ALT, AST, bilirubin) | Baseline; repeat for symptoms or risk factors (here at two to three weeks, for low weight and albumin) | Completed today | ALT 22 U/L at the end of treatment |
| Laboratory | Hemoglobin and albumin | At the end of treatment when low at baseline | Completed today | Hemoglobin 14.1 g/dL; albumin 4.0 g/dL |
| Laboratory | Sputum acid-fast smear and culture | Baseline, then monthly until two consecutive cultures are negative | Completed today | Two consecutive negative cultures (third week and two months); no further sputum needed |
| Laboratory | Two-month sputum culture | At the end of the intensive phase; a positive result needs evaluation and repeat susceptibility testing | Completed today | No growth |
| Imaging | Chest X-ray | Baseline; at two months only if baseline cultures were negative; end of treatment optional | Completed today | Cavity closed; small area of right upper lobe scarring |
| Medication safety | Doses observed and the completion clock (56 doses within 70 days, 63 within 84 days, 119 within five months) | Every visit | Completed today | 119 doses in 17 weeks, within five months |
| Referral | Notification of treatment completion | At the end of treatment | Completed today | Sent to the health department today |
| Survey | Depression screen (PHQ-9) | At diagnosis, at two months, and at the end of treatment | Completed today | 3, item 9 scored 0 |
| Self-management | Nutrition: dietitian, intake, supplement drinks | Every visit until weight is restored | Completed today | Weight goal met; supplements stopped |
| Referral | Infectious diseases review | At diagnosis, at two months, and at the end of treatment | Completed today | Results reviewed by message; no routine follow-up |

## Goal progress

- Complete all 119 doses within five months by video-observed therapy. Outcome by 2026-07-21: All 119 doses completed in 17 weeks: 56 in the intensive phase and 63 in the continuation phase, with none missed. **S**
- Sputum culture negative at two months. Outcome by 2026-07-21: The two-month culture showed no growth, as did the cultures from the third week. **S**
- Return to teaching once the health department confirms he is no longer infectious. Outcome by 2026-04-07: Released from isolation after three negative smears and more than two weeks of treatment; teaching again from the third week. **S**
- Weight back to at least 55 kg by the end of treatment. Outcome by 2026-07-21: 55.0 kg at the end of treatment, from 48.5 kg at diagnosis. **S**
- PHQ-9 below 5 by the end of treatment. Outcome by 2026-07-21: PHQ-9 3 at the end of treatment, from 7 at diagnosis. **S**

## Guideline basis

- Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016), American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America (Clinical Infectious Diseases)
- Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022 (2022), Centers for Disease Control and Prevention (MMWR)
- An official ATS statement: hepatotoxicity of antituberculosis therapy (2006), American Thoracic Society (American Journal of Respiratory and Critical Care Medicine)
- Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC (2005), Centers for Disease Control and Prevention (MMWR Recommendations and Reports)
- Consensus statement: Academy of Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition: characteristics recommended for the identification and documentation of adult malnutrition (undernutrition) (2012), Academy of Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition (JPEN)
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force

## Follow-up

- Adult preventive visit in about two months. Same-day visit for symptoms of relapse. **S**
- Next scheduled visit 2026-09-15: adult preventive visit. **S**
